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Summary
Background Global child mortality reduced substantially during the Millennium Development Goal period (2000–15). 
We aimed to estimate morbidity, mortality, and prevalence of risk factors for child pneumonia at the global, regional, 
and national level for developing countries for the Millennium Development Goal period.
Methods We estimated the incidence, number of hospital admissions, and in-hospital mortality due to all-cause 
clinical pneumonia in children younger than 5 years in developing countries at 5-year intervals during the Millennium 
Development Goal period (2000–15) using data from a systematic review and Poisson regression. We estimated the 
incidence and number of cases of clinical pneumonia, and the pneumonia burden attributable to HIV for 
132 developing countries using a risk-factor-based model that used Demographic and Health Survey data on 
prevalence of the various risk factors for child pneumonia. We also estimated pneumonia mortality in young children 
using data from multicause models based on vital registration and verbal autopsy.
Findings Globally, the number of episodes of clinical pneumonia in young children decreased by 22% from 178 million 
(95% uncertainty interval [UI] 110–289) in 2000 to 138 million (86–226) in 2015. In 2015, India, Nigeria, Indonesia, 
Pakistan, and China contributed to more than 54% of all global pneumonia cases, with 32% of the global burden from 
India alone. Between 2000 and 2015, the burden of clinical pneumonia attributable to HIV decreased by 45%. Between 
2000 and 2015, global hospital admissions for child pneumonia increased by 2·9 times with a more rapid increase 
observed in the WHO South-East Asia Region than the African Region. Pneumonia deaths in this age group decreased 
from 1·7 million (95% UI 1·7–2·0) in 2000 to 0·9 million (0·8–1·1) in 2015. In 2015, 49% of global pneumonia 
deaths occurred in India, Nigeria, Pakistan, Democratic Republic of the Congo, and Ethiopia collectively. All key risk 
factors for child pneumonia (non-exclusive breastfeeding, crowding, malnutrition, indoor air pollution, incomplete 
immunisation, and paediatric HIV), with the exception of low birthweight, decreased across all regions between 2000 
and 2015.
Interpretation Globally, the incidence of child pneumonia decreased by 30% and mortality decreased by 51% during 
the Millennium Development Goal period. These reductions are consistent with the decrease in the prevalence of 
some of the key risk factors for pneumonia, increasing socioeconomic development and preventive interventions, 
improved access to care, and quality of care in hospitals. However, intersectoral action is required to improve 
socioeconomic conditions and increase coverage of interventions targeting risk factors for child pneumonia to 
accelerate decline in pneumonia mortality and achieve the Sustainable Development Goals for health by 2030.
Funding Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Global child mortality, including pneumonia mortality, 
has decreased substantially since 2000; however, 
mor tality remains high: an estimated 921 000 children 
younger than 5 years died of pneumonia in 2015.1 
In addition to monitoring mortality, it is important 
to monitor the underlying incidence of childhood 
pneumonia to inform preventive intervention strategies 
and health service planning, because the burden of 
pneumonia on both in-patient and out-patient health-
care services is sub stantial. We previously published 
the first global estimates of clinical pneumonia 
incidence for young children for the year 2000 
(155·8 million cases),2 and subsequently updated these 
estimates for 2010 (120·4 million cases).3 However, data 
on HIV and measles immunisation status (two key risk 
factors for pneumonia in young children) were not 
included in the model used to estimate clinical 
pneumonia episodes at the country level.4 We have 
since developed an improved risk-factor-based model 
incorporating HIV and measles immunisation data and 
have reported that the overall global pneumonia 
morbidity estimates from this new model are consistent 
with those reported using the previous approach.5 We 
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also reported the first global estimates of clinical 
pneumonia episodes in young children with HIV in 
2010 (approximately 1·4 million episodes), of which 
86% of cases were attributable to HIV.5 We have also 
reported the first global and regional 2010 estimates for 
hospital admissions due to pneumonia in young 
children (11·9 million admissions).6
In this paper, we provide updated estimates of the 
incidence of all-cause clinical and severe pneumonia and 
the morbidity attributable to HIV in young children 
during the Millennium Development Goal period 
(2000–15) with estimates for both 2000 and 2015. We 
provide global estimates, overall estimates for developing 
countries, and country-level estimates for 132 developing 
countries with high pneumonia mortality. We also 
estimate the burden of hospital admissions due to 
pneumonia and pneumonia mortality for 2000 and 2015.
Methods
Search strategy and selection criteria
We did a systematic literature review with various search 
terms. We searched MEDLINE, Embase, Global Health, 
and LILACS for community-based studies published 
between Jan 1, 1980, and Dec 31, 2016. Full search terms 
are provided in the appendix. We also manually searched 
reference lists of included papers to identify any 
additional studies not identified using our search 
strategy. We also searched three Chinese language 
databases (China National Knowledge Infrastructure, 
Wanfang, and Chongqing VIP) for studies published in 
Chinese. We included studies that reported the incidence 
of WHO-defined clinical pneumonia7 (defined as cough 
or difficulty breathing with tachypnoea) done in 
developing countries (classified according to UNICEF 
definitions8). We defined low-income and middle-income 
countries on the basis of the World Bank classification.9 
We included countries that reported high pneumonia 
mortality in our previous estimates. Countries without 
Demographic and Health Surveys (DHS) data were 
excluded. Full eligibility criteria for the systematic 
analysis are shown in the panel.
Data analysis
DA and IR independently extracted incidence data, and JB 
and TS independently extracted hospital admission data. 
Any discrepancies regarding the inclusion of studies or 
data extraction were resolved by HN. TS searched and 
extracted data from the Chinese literature. If more than 
one publication from the same study was identified, we 
included the paper that reported data for the longest study 
duration. We estimated the predicted incidence rates of 
clinical pneumonia in developing countries at 5-year 
intervals for the period 2000–15 using Poisson regression. 
We used Markov chain Monte Carlo (MCMC) sampling 
within the JAGS software package10 because this approach 
allowed us to readily incorporate the uncertainty in these 
estimates into our previous risk-factor-based pneumonia 
morbidity model for country specific estimates.5 From all 
clinical pneumonia studies, we identified a subset of 
studies that reported the proportion of clinical pneumonia 
cases with lower chest wall indrawing (to estimate severe 
pneumonia). Since we expected significant heterogeneity 
in the data, we did random-effects meta-analyses to 
estimate the overall proportion for developing countries, 
Research in context
Evidence before this study
In 2000, we published global estimates for clinical pneumonia 
(155·8 million cases) and severe pneumonia (13·1 million cases), 
and pneumonia deaths (2·1 million deaths) in children younger 
than 5 years. We subsequently updated these estimates for 2010 
(clinical pneumonia [120·4 million cases] and severe pneumonia 
[14·1 million cases]) and published the first estimates of 
pneumonia episodes attributable to HIV (1·4 million cases) and 
hospital admissions for pneumonia (11·9 million admissions) in 
young children (<5 years) in 2010. We have also published 2015 
estimates of pneumonia deaths (921 000 deaths) in young 
children (<5 years). The Institute for Health Metrics and 
Evaluation (IHME) estimated 101·8 million episodes of 
pneumonia (95% uncertainty interval [UI] 90·0–114·4) and 
0·7 million pneumonia deaths (95% UI 0·7–0·8) in this age group 
in 2015 and reported a 37% decrease in morbidity and mortality 
between 2005 and 2015. The IHME also estimated that globally, 
8·9% of the decrease in disability-adjusted life-years lost due to 
lower respiratory infections in children younger than 5 years 
during this period was attributable to reductions in childhood 
malnutrition and 4·3% to decreased exposure to air pollution.
Added value of this study
We present updated national estimates of child pneumonia 
morbidity and mortality for the Millennium Development Goal 
period (2000–15). We incorporate new data from ten studies 
reporting incidence of clinical pneumonia and 30 studies 
reporting hospital admission rates due to pneumonia in young 
children, and use improved methods to yield a valid time-series 
analysis. We also provide an in-depth analysis of the seven key risk 
factors for child pneumonia, and assess the relative contribution 
of these (particularly HIV) to changes in pneumonia burden.
Implications of all the available evidence
Our systematic analysis provides the most up-to-date estimates 
of morbidity and mortality for child pneumonia in the 
Millennium Development Goal period. These estimates update 
previously published estimates and highlight global progress 
towards reducing the morbidity and mortality from child 
pneumonia and identify areas that require targeted 
interventions (especially reducing the prevalence of risk factors 
for child pneumonia) and can be used to inform national child 
health intervention strategies.
See Online for appendix
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which was applied to the estimated incidence of 
clinical pneumonia to estimate the incidence of severe 
pneumonia at each 5-year timepoint between 2000 and 
2015. We used our pneumonia mor bidity model to 
estimate the incidence of clinical pneu monia and severe 
pneumonia in developing countries.5 We stratified all 
developing countries into WHO sub regions on the 
basis of child and adult mortality data.11 We used 
individual participant-level data on all key risk 
factors for child pneumonia (low birthweight, crowding, 
malnutrition, non-exclusive breastfeeding, indoor air 
pollution, in complete immunisation, and paediatric HIV)4 
from DHS, with the exception of data on prevalence of 
paediatric (<5 years) HIV, which were obtained from 
UNAIDS, for all developing countries except China (data 
obtained from the National Bureau of Statistics of China) 
in the years closest to years 2000 and 2015 to calculate the 
proportion of participants with each combination of risk 
factors. If country-level prevalence data were not available 
for any risk factor, we imputed the median prevalence for 
the subregion. We used the model to calculate country-
specific incidence rates (appendix). In our models, we 
assumed that the incidence of pneumonia in children 
without these seven risk factors would be similar within 
a region, risk ratios could be multiplied when two or 
more risk factors were present, and risk factors were 
independently distributed within countries. We also 
calculated the incidence of clinical pneumonia in children 
with HIV and incidence of pneumonia attributable to HIV.
We also updated our 2013 review6 reporting the number 
of hospital admissions due to child pneumonia (on the 
basis of physician’s diagnosis and judgment that hospital 
care was indicated) and in-hospital case fatality ratio 
(hCFR) and included any studies published between 
April 1, 2012, and Dec 31, 2016, which satisfied our 
eligibility criteria (panel). We used Poisson regression 
with MCMC sampling in JAGS (10 000 samples) to 
estimate the predicted rate of hospital admissions and 
hCFR at 5-year intervals between 2000 and 2015. Since we 
had substantial data for all WHO regions for the period 
1995–2015, we reported hospital admissions and hCFR 
estimates by WHO region. We also estimated the 
proportion of child pneumonia episodes that were treated 
in hospital (using the number of episodes with lower 
chest wall indrawing since the denominator for these 
cases would have been eligible for hospitalisation as per 
the WHO recommendations that applied at that time). 
We also estimated pneumonia mortality burden for 
2000–15. The numbers of deaths and mortality due to 
pneumonia were calculated separately for neonates 
and children aged 1–59 months. Estimates were derived 
by applying the estimated age-specific pneumonia 
mortality fraction to age-specific all-cause number of 
deaths and mortality rates from the UN Inter-Agency 
Group for Child Mortality Estimation.12 To generate 
the age-specific pneumonia mortality fractions, we used 
vital registration data in countries with adequate vital 
Panel: Eligibility criteria for studies included in the 
systematic analysis
Inclusion criteria
• Studies published between Jan 1, 1980, and Dec 31, 2016, 
which reported acute lower respiratory infections among 
children in developing countries
• Studies reporting incidence of clinical pneumonia in 
children aged younger than 5 years or the number of 
episodes of clinical pneumonia with a clear denominator 
population at risk in developing countries
• Studies reporting number of hospital admissions for 
pneumonia in children aged younger than 5 years or 
number of hospital admissions for pneumonia in this age 
group with a clear denominator population at risk (well 
defined catchment population)
Exclusion criteria
Clinical pneumonia
• Studies that are not community-based longitudinal studies
• Studies that do not estimate the incidence of clinical 
pneumonia
• Studies that are not community-based surveillance of a 
predefined population of children
• Studies not reporting data for a minimum of 
12 consecutive months (or multiples thereof)
• Studies without active case detection
• Studies with surveillance intervals longer than 2 weeks
• Studies with case definitions not clearly defined and 
consistently applied
Pneumonia treated in hospital
• Studies not reporting data for a minimum of 
12 consecutive months (or multiples thereof)
• Studies without a clear description of the methods for 
estimating denominator population
• Studies not reporting data for all-cause pneumonia
• Studies reporting only aetiology specific or chest 
radiograph confirmed pneumonia
• Studies with case definitions not clearly defined and 
consistently applied
• Studies reporting hospital admissions using modelling 
techniques
registration systems, vital-registration-based multicause 
models for countries with inadequate vital registration 
systems and low under-5 mortality rate (U5MR), and 
verbal-autopsy-based multicause models for countries 
with high U5MR. We used post-hoc adjust ment to assess 
the effect of pneumococcal conjugate vaccines and 
Haemophilus influenzae type b vaccine on pneumonia 
mortality. Detailed methods are available elsewhere.1
All statistical analyses were done using R (version 3.2; 
Vienna, Austria), JAGS (version 3.4), and Stata (version 11.1). 
This study was done in accordance with the Guidelines for 
Accurate and Transparent Health Estimates Reporting 
(GATHER) recommendations (appendix).
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Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
DAM, LL, and HN had full access to all the data in the 
study and HN had the final responsibility for the decision 
to submit for publication.
Results
We identified 45 community-based studies (done between 
Jan 1, 1980, and Dec 31, 2016) reporting incidence of 
clinical pneumonia in children younger than 5 years 
(figure 1; appendix). References for all included studies 
are listed in the appendix. One study reported 
implementation of pneumococcal conjugate vaccines and 
H influenzae type b vaccination programmes at study 
sites during the study period.13 40 (89%) of 45 studies 
used the WHO Integrated Management of Childhood 
Illness (IMCI) case definitions for pneumonia.7 On the 
basis of these data, we estimated that the annual incidence 
of clinical pneumonia in young children in developing 
countries decreased from 329 episodes per 1000 children 
(95% UI 201–537) in 2000 to 231 episodes per 
1000 children (141–377) in 2015 (appendix). Across 
developing countries, the number of episodes of clinical 
pneumonia in children younger than 5 years decreased 
from 178 million (95% UI 110–289) in 2000 to 138 million 
(86–226) in 2015, which corresponds to a 30% decrease in 
incidence and a 22% decrease in number of annual 
episodes of clinical pneumonia in young children during 
the 15-year period. We also identified 13 studies (appendix) 
from developing countries that reported the proportion of 
cases of clinical pneumonia with lower chest wall 
indrawing (ie, severe pneumonia). The meta-estimate of 
the proportion of cases classified as severe was 16% 
(95% CI 7–39; appendix), which we assumed was fixed 
across years. This proportion indicates that the number 
of episodes of severe pneumonia in young children 
decreased from 28 million (95% UI 18–46) in 2000 to 
22 million (14–36) in 2015.
We analysed the difference in prevalence of risk factors 
for clinical pneumonia at both country and regional 
levels. We observed that country-level estimates for 
prevalence of a specific risk factor for clinical pneumonia 
varied substantially across the DHS. At the regional level, 
the prevalence of most risk factors decreased between 
2000 and 2015 (figure 2). The proportion of children who 
were mal nourished decreased across all regions (ranging 
from a 7% decrease in the South-East Asia Region to 
a 72% decrease in the Western Pacific Region), as did the 
proportion of children with incomplete immunisation 
(ranging from a 5% decrease in the South-East Asia 
Region to a 61% decrease in the Western Pacific Region). 
However, the proportion of newborn babies with a low 
birthweight increased across all regions between 2000 
and 2015 (ranging from a 9% increase in the Region of 
the Americas to a 67% increase in the Western Pacific 
region). In 2015, in developing countries, an estimated 
317 million (95% UI 316–318) children younger than 
5 years were exposed to indoor air pollution, 270 million 
(269–271) were exposed to overcrowding, and 146 million 
(145–147) were exposed to non-exclusive breastfeeding 
(appendix). In the African Region in 2015, 126 million 
(95% UI 126–127) children younger than 5 years 
were exposed to indoor air pollution and 935 000 
(876 000–994 000) children were exposed to HIV. In the 
South-East Asia Region, 125 million (95% UI 124–125) 
children younger than 5 years were exposed to indoor 
air pollution and this remained unchanged from 2000 
(appendix).
In 2000, at the country level, the annual incidence of 
clinical pneumonia and severe pneumonia in children 
younger than 5 years ranged from 598 episodes per 
1000 children (95% UI 325–1122) and 95 episodes per 
1000 children (35–233), respectively, in Afghanistan to 
151 (78–287) and 24 (8–60), respectively, in Egypt (appendix). 
In 2000, India, China, Indonesia, Nigeria, and Bangladesh 
contributed to more than 50% of cases of clinical pneu-
monia and severe pneumonia in developing countries. 
In 2015, at the country level, the annual incidence of 
clinical pneumonia and severe pneumonia ranged from 
484 episodes per 1000 children (95% UI 268–895) and 
Figure 1: Flow diagram for selection of studies for clinical pneumonia
993 full-text articles excluded
800 had no relevant data
98 were not community-based
35 did surveillance for <1 year
22 had no or unclear 
population denominator
16 done before 1980
13 with case definitions not 
clearly defined and 
consistently applied
4 had surveillance intervals 
>2 weeks
4 studies excluded children in 
first 6 months of life
1 had no full-text available
23 634 records identified 
from database search
9 records identified through 
other sources
13 293 records excluded because not 
relevant to topic
14 331 records after duplicates removed
14 331 records screened
1038 full-text articles assessed for eligibility
45 studies reporting data from 46 sites 
included in the analysis
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78 episodes per 1000 children (29–188), respectively, in 
Afghanistan to 84 (40–166) and 14 (5–34), respectively, in 
China (figure 3; appendix). In 2015, India, Nigeria, 
Indonesia, Pakistan, and China contributed to more than 
54% of the cases of clinical pneumonia and severe 
pneumonia. The incidence of clinical pneumonia and 
severe pneumonia decreased by at least 25% in 99 (75%) of 
132 developing countries, with the highest reduction 
observed in China (around 69%; figure 3; appendix). We 
also estimated that episodes of clinical pneumonia and 
severe pneumonia decreased by at least 25% in 72 (55%) of 
132 developing countries with the highest reductions in 
China and Malaysia (68–69%; appendix). Our analysis 
indicates that the incidence of clinical pneumonia and 
severe pneumonia increased in Pakistan by about 50% with 
a concomitant rise in the number of episodes by about 
75%. In 2000 and 2015, India had the highest number of 
episodes of clinical pneumonia (32% of all episodes in 
developing countries) and the number of pneumonia 
episodes decreased by only 3% during this 15-year period.
Across the 132 developing countries included, episodes of 
clinical pneumonia in children younger than 5 years with 
HIV decreased from 3·1 million (95% UI 1·9–5·3) in 2000 
to 1·7 million (1·0–2·9) in 2015 (appendix). Overall, 
episodes of clinical pneumonia attributable to HIV 
decreased from 2·5 million (95% UI 1·5–4·3) in 2000 to 
1·4 million (0·8–2·4) in 2015, which corresponds to 
a 45% reduction in episodes of clinical pneumonia in 
children with HIV younger than 5 years during this 15-year 
period. In 33 (25%) of the 132 developing countries, 
pneumonia incidence decreased by more than 50% and in 
93 (70%) incidence decreased by at least 25% during this 
period (appendix). In 11 countries, the number of episodes 
of clinical pneumonia in children with HIV decreased by 
more than 70%, and 59% of developing countries reported a 
reduction of at least 33% in the number of pneumonia 
cases in children with HIV. 14 countries reported an 
increase in the episodes of clinical pneumonia in children 
with HIV (ranging from 5% in Nigeria to 104% in Equatorial 
Guinea). Of these 14 countries, only Nigeria and 
Mozambique are included in the UNAIDS Global Plan.14 
The proportionate contribution of sub-Saharan Africa to the 
global estimates of clinical pneumonia in children with 
HIV decreased from 78% in 2000 to 72% in 2015.
We updated our 2013 systematic review of hospital 
admissions for pneumonia in children younger than 
5 years and identified 18 new studies reporting the 
number of hospital admissions (appendix). During 
the 15-year period, the number of hospital admissions 
due to pneumonia in low-income countries increased 
Figure 2: Prevalence of risk factors for child pneumonia (2000–15)
Data are from country-level Demographic and Health Surveys for the years closest to 2000 and 2015. Bold coloured lines indicate the proportion of children with the 
risk factor at the WHO regional level. Grey lines indicate the proportion of children with the risk factor at the country level.
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by 320% compared with around 155% for middle-
income countries (figure 4; appendix). The proportion 
of children with severe pneumonia who were admitted 
to hospital in low-income countries increased by 
7·6 times (from 7% to 50%) and by 3·5 times 
(from 23% to 80%) in middle-income countries in this 
15-year period. The increase in hospital admissions was 
higher in the South-East Asia Region than the African 
Region (appendix). In low-income and middle-income 
countries, the number of children admitted to hospital 
due to pneumonia increased by 187%, from 5·7 million 
(95% UI 3·5–9·5) in 2000 to 16·4 million (9·8–28·0) in 
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Figure 3: Change in incidence of clinical pneumonia in children younger than 5 years in 132 developing countries between 2000 and 2015
Error bars show 95% uncertainty intervals. 95% uncertainty intervals for some 2000 estimates were wide and the upper limits exceeded the scale used.
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2015 (appendix). Overall, hospital admissions for child 
pneumonia increased by 2·9 times during the 15-year 
period. We also identified 27 new studies reporting 
hCFR for hospital admissions due to pneumonia 
(appendix) and observed a substantial decline in hCFR 
during this period (figure 5). The decline was faster in 
the South-East Asia Region than the African Region 
(appendix).
Globally, the number of deaths due to pneumonia 
among children younger than 5 years was 0·9 million 
(95% UI 0·8–1·1) in 2015, with more than 80% of deaths 
occurring in those aged 1–59 months (0·8 million 
[0·7–0·9]; appendix). Between 2000 and 2015, the 
burden of pneumonia deaths decreased substantially. 
Specifically, the number of deaths due to pneumonia 
decreased by nearly half, from 1·7 million (95% UI 
1·7–2·0) in 2000 to 0·9 million (0·8–1·1) in 2015 
(appendix). Globally, pneumonia-specific mortality 
among children younger than 5 years decreased from 
13·6 per 1000 livebirths (95% UI 12·9–15·4) in 2000 to 
6·6 per 1000 livebirths (5·8–8·0) in 2015, with the 
largest contribution to total decrease in U5MR among 
all causes. In developing countries, pneumonia-specific 
mortality decreased from about 15·2 per 1000 livebirths 
(95% UI 14·3–17·3) in 2000 to about 7·4 per 
1000 livebirths (6·7–8·8) in 2015. The CFR for clinical 
pneumonia decreased from 0·96% in 2000 to 0·65% in 
2015 and from 6·1% to 4·2% for severe pneumonia 
during the same period.
In 2015, the WHO African Region had the highest 
burden of pneumonia deaths (0·5 million [95% UI 
0·4–0·6]) among children younger than 5 years, followed 
by the South-East Asia Region (0·2 million [0·2–0·3]). 
Taken together, the two regions accounted for more than 
three-quarters of global pneumonia deaths in children 
younger than 5 years. The five countries with the highest 
number of pneumonia deaths in children younger 
than 5 years were India, Nigeria, Pakistan, Democratic 
Republic of the Congo, and Ethiopia (appendix), 
accounting for 49% of global pneumonia deaths 
collectively. The five countries with the highest 
pneumonia mortality rates were Somalia, Chad, Angola, 
Central African Republic, and Niger (appendix).
Discussion
We report regional-level and country-level estimates for 
clinical pneumonia and hospital admissions due to 
pneumonia in young children (aged <5 years) during 
a 15-year period (2000–15) using a time-trend analysis. 
Globally, the incidence of clinical pneumonia in young 
children decreased by 30% and the number of episodes 
of clinical pneumonia decreased by 22% during this 
period. The number of episodes of clinical pneumonia in 
children with HIV decreased by 45% in this age group, 
with an increasing proportion of episodes occurring in 
non-African countries. Data from hospital-based studies 
indicate a 187% increase in hospital admissions due to 
child pneumonia between 2000 and 2015. Additionally, 
pneumonia mortality decreased by 51% in this age group 
during the 15-year period.
Figure 4: Change in rate of hospital admissions due to pneumonia in low-
income and middle-income countries between 1990 and 2015
Shaded bands show 95% uncertainty intervals. Estimates for 2000 were based on 
data obtained between 1980 and 2000.
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Figure 5: In-hospital case fatality rate for young children admitted to 
hospital with pneumonia in low-income and middle-income countries 
between 2001 and 2015
Shaded bands show 95% uncertainty intervals.
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unadjusted global estimates for child pneumonia deaths 
in 2000 and 2015 were 1·76 million and 1·09 million, 
respectively (appendix). In our mortality estimates, we 
accounted for some sources of uncertainty, such as 
random sampling error and uncertainty from all-cause 
mortalities, but did not account for other important 
sources, including model uncertainty, uncertainty 
around covariate values, and uncertainty associated with 
misclassification of causes of deaths, particularly when 
data from verbal autopsy were used.
About 90% of the included studies used the 2005 
WHO-IMCI case definitions for clinical pneumonia.7 
These case definitions were developed for programmatic 
purposes for use by community health workers and thus 
are highly sensitive. These definitions have been widely 
adopted, understood, and used by national control 
programmes. Continued adoption of these widely 
accepted definitions over time provides a secure basis 
from which to assess trends and provides estimates 
that can be understood in terms of national control 
programmes in developing countries since WHO 
guidelines that recommend the use of these clinical 
definitions are widely used in these programmes. 
However, use of these case definitions is likely to lead to 
overestimation of true pneumonia in most settings due 
to the relatively low specificity of clinical pneumonia 
(around 70%) and low prevalence of pneumonia 
compared with children who have cough and difficult 
breathing.18,19 Moreover, this clinical pneumonia defin-
ition, which is based on simple clinical signs, encom-
passes various lower respiratory infections ranging from 
bronchiolitis to radiologically confirmed pneumonia.20 
The use of this case definition has had substantial effect 
at a programmatic level. On one hand, the high detection 
rate for pneumonia had resulted in a substantial decline 
in pneumonia mortality; however, on the other hand, a 
level of overprescription of antibiotics has been accepted, 
which is a matter of concern with regard to widespread 
antimicrobial resistance. Several experts have proposed 
that cases diagnosed in this way should be defined as 
WHO pneumonia (based on simple clinical signs) to 
better distinguish from physician-diagnosed pneumonia. 
The previous WHO case definition for severe pneumonia 
is based on lower chest wall indrawing alone, which often 
overestimates the proportion of children with pneumonia 
who required referral to hospital. WHO revised the 
definition for severe pneumonia in 2014,21 restricting this 
to children with signs of pneumonia who also had so-
called danger signs, such as reduced conscious level and 
inability to drink. However, none of the included studies 
used the revised case definitions. The adoption of these 
revised case definitions is expected to result in improved 
pneumonia case management in the community and a 
lower number of hospital admissions over time.22 The 
effect of these revised guidelines on pneumonia mortality 
in populations with poor access to health care is 
uncertain.23
Our current morbidity estimates used improved 
methods compared with previous estimates, such as the 
inclusion of data from Chinese language databases, 
a model based on seven risk factors instead of five, Poisson 
regression with MCMC sampling in JAGS to report 
uncertainty ranges, use of individual-level data rather than 
aggregate data from large-scale surveys, and the assum-
ption that risk factors were independently distributed 
rather than mutually exclusive. We used these methods to 
recalculate the 2000–15 estimates to yield a valid time-
series analysis. The new estimates are thus not directly 
comparable with our previous 2000 and 2010 estimates 
for clinical pneumonia or hospital admissions due to 
pneumonia.3,6 Our pneumonia morbidity and mortality 
estimates are also higher than those reported by the 2015 
Global Burden of Disease Study.15 Those authors reported 
global estimates of 101·8 million (95% UI 90·0–114·4) 
episodes of pneumonia and 0·7 million (0·7–0·8) 
pneumonia deaths in this age group with a 37% decrease 
in morbidity and mortality between 2005 and 2015. In 
2015, we published a review16 comparing the methods used 
by our group and the Global Burden of Disease group and 
identified a number of key differences. Our group used 
UN Population Division census estimates on number of 
children nationally and globally and the UN Inter-Agency 
Group on Mortality Estimation estimates on numbers 
of child deaths to promote global consensus and 
consistency, which are not currently used by the Institute 
for Health Metrics and Evaluation. For cause of death 
modelling within child deaths, our group used stricter 
inclusion criteria (requiring higher levels of completeness 
and representativeness to minimise selection biases) for 
verbal autopsy and vital registration data and attempted to 
avoid using data from high-income countries to estimate 
cause of death patterns in low-income and middle-income 
settings, which have substantially different epidemiology. 
We also attributed the neonatal causes differently 
across pneumonia, sepsis, and meningitis categories. This 
exercise was a useful first step in attempting to harmonise 
global estimates. Further progress requires that all 
research groups adhere to the minimum reporting require-
ments con tained in the GATHER recom mendations 
with increasing willingness to share details of datasets, 
data processing (including analysis code), and covariates. 
Ideally, we can move towards a position in which there is 
agreement on a common set of covariates and modelling 
groups would be able to access an agreed common 
dataset.17
Several sources of uncertainty exist in our morbidity 
estimates: case definitions, coverage of pneumococcal 
conjugate vaccines and H influenzae type b vaccine in 
children, prevalence data for the risk factors for 
pneumonia, limited data on the proportion of clinical 
pneumonia that are classified as severe, and assumptions 
of independence. Our mortality estimates include a post-
model adjustment for pneumococcal conjugate vaccines 
and H influenzae type b vaccines in children.1 The 
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Between 2000 and 2015, incidence of both clinical and 
severe pneumonia decreased by 30%, case fatality rate 
decreased by 32%, and mortality by 50% for child 
pneumonia. The decrease in pneumonia incidence 
during this period is consistent with the decrease in the 
number of children exposed to some of the key risk 
factors for pneumonia (HIV, incomplete immunisation 
[measles vaccination], malnutrition, and overcrowding 
[figure 2; appendix]). However, increases in the number 
of children born with a low birthweight, and those 
exposed to indoor air pollution and non-exclusive 
breastfeeding (both amenable to low-cost interventions 
and behavioural change), are a cause of concern and an 
area for targeted action. We postulate that the reduction 
in pneumonia mortality is a result of both decrease in 
incidence, due to reduced risk factor exposure with 
increasing socioeconomic development and preventive 
interventions, and a decrease in case fatality rate, which 
is a result of improved access to care, likely lowering of 
the threshold for hospital admission, and improved 
quality of care in hospitals. The decrease in incidence of, 
and mortality from, childhood pneumonia during this 
period is a result of interconnected social, economic, 
political, health system, and health programme factors.24 
The decrease can be partly attributed to the introduction 
and scale-up of vaccines against bacterial pneumonia 
(H influenzae type b and Streptococcus pneumoniae). 
Although in 2015, the estimated coverage for three doses 
of H influenzae type b and pneumococcal conjugate 
vaccines received by infants was 63% and 37%, 
respectively (with wide variations between regions and 
within countries),25 only one of the 45 community-based 
studies included in our analysis reported implementation 
of pneumococcal conjugate vaccines and H influenzae 
type b immunisation in the population. Three doses 
of H influenzae type b and pneumococcal conjugate 
vaccines individually are estimated to reduce the 
incidence of clinical pneumonia by 4% and 7%, 
respectively, and severe pneumonia by 6% and 7%, 
respectively.26 Thus, although we did not adjust our 
estimates for clinical pneumonia and severe pneumonia 
for vaccine coverage, we do not think we have over-
estimated the incidence of clinical pneumonia and severe 
pneumonia at the global level.
The data on prevalence of the risk factors for pneumonia 
were obtained from country-level DHS datasets. DHS data 
have several limitations, including the small number of 
repeat surveys, poor consistency in prevalence estimates 
between surveys, and absence of prevalence data on one or 
more risk factors for some countries. Caution should be 
taken when interpreting data for the Western Pacific 
Region because of the small number of countries that 
contributed to the 2000 DHS. We only used prevalence 
data from surveys for years closest to 2000 and 2015, and if 
data were not available for a specific country, we imputed 
the median prevalence of the risk factor in the WHO 
subregion. We have also been unable to account for wide 
intracountry variations in socioeconomic conditions and 
associated risk factor prevalence in populations residing 
in middle-income countries, which would account for 
the high hetero geneity in pneumonia incidence in 
large countries such as India and China. Furthermore, 
the absence of independence among risk factors is an 
important limitation. We modelled the effect of relaxing 
this assumption for clinical pneumonia using individual-
level data from 102 DHS, and found that, since the 
marginal proportions for each risk factor were relatively 
low, the impact of the assumption of independence on 
incidence estimates was low (appendix).
The 187% increase in hospital admissions due to child 
pneumonia between 2000 and 2015 reflects improving 
access to hospital care in the public and private sectors. 
This increase supports the current focus on improving 
quality of care in hospitals and the efforts of WHO and 
UNICEF in launching a Network for Improving Quality 
of Care for Maternal, Newborn and Child Health.27 The 
increase in hospital admissions also underlines the 
importance of health-care planning to ensure adequate 
capacity in future and focusing hospital referral and 
admission of children with the poorest prognosis (such 
as those with hypoxaemia) who would benefit most 
from inpatient care so that hospital resources are used 
efficiently and are not overwhelmed by the increase in 
patient load.
These disease burden estimates do not include 
the long-term sequelae that accompany pneumonia 
episodes in young children. Pneumonia leads to 
interstitial lung damage and reduced future alveolar 
growth leading to reduced lung capacity and increased 
risk of chronic lung disease. The increased risk of 
restrictive lung disease (such as chronic suppurative 
lung diseases like bronchiectasis and chronic bronchitis) 
is well docu mented in both case-control and large 
population cohort studies, whereas the risk of obstruc-
tive lung disease is less clear at present.28 The incidence, 
hospital admission rate, case fatality rates, and risk 
factors for child pneumonia are likely to be age 
dependent. However, most of the included studies did 
not report results using narrow age bands, which in 
turn limited our ability to report age-specific estimates 
that could be used for targeted interventions. A small 
number of studies13,29,30 has shown that children without 
HIV infection who were exposed to the virus prenatally 
(HIV-exposed uninfected; HEU) have intermediate 
disease severity and are less likely to respond to 
treatment than children with HIV and children who 
have not been exposed to the virus. However, country-
level data on the prevalence of pneumonia in HEU 
children are not available at present. Moreover, little 
evidence is available regarding pneumonia mortality in 
this population of children.30,31 Therefore, we did not 
include HEU as a risk factor in our analysis.
Global funding for child pneumonia more than doubled 
in the period 2008–2013 (from US$306 million to 
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$663 million), with most funding allocated to south Asia 
and sub-Saharan Africa, where the majority of child 
pneumonia deaths occur.32 In 2011, 69% of the pneumonia 
funding was allocated to sub-Saharan Africa. However, the 
progress in improving care and reducing pneumonia 
mortality has not been equitable between the two regions. 
Hospital admissions due to pneumonia increased more 
rapidly in south Asia than Africa, whereas hCFR decreased 
more rapidly in south Asia than Africa between 2000 and 
2015. The decrease observed in south Asia indicates a 
marked improvement in access to hospital care, care-
seeking behaviour, and quality of hospital care. These 
reductions are consistent with a 2016 UNICEF report,33 
which showed that three of five children with signs of 
pneumonia seek care in south Asia compared with only 
two of five children in sub-Saharan Africa, where the 
majority of pneumonia deaths occur. Substantial efforts 
need to be made in sub-Saharan Africa if further 
improvements in access to hospital care and reductions in 
pneumonia mortality are to be achieved.
The rate of decline in child pneumonia mortality needs 
to accelerate to achieve the Sustainable Development 
Goals for health by 2030.34 Future reductions in 
pneumonia disease burden will require continued 
socioeconomic development (with attention to mini-
mising population inequities) together with integrated, 
multisectoral action to protect (by exclusive breastfeeding 
and complementary feeding and micronutrient supple-
mentation), prevent (timely immunisation, HIV pre-
vention, cotrimoxazole prophylaxis, reduction of air 
pollution, and improved handwashing and sanitation) 
and treat (improved care seeking, treatment and referral, 
and continued feeding) pneumonia according to 
strategies advocated in the WHO Global Action Plan 
against Pneumonia and Diarrhoea.35 Intersectoral action 
will be required to reduce fertility, improve socio economic 
conditions, increase coverage of interventions targeting 
risk factors for child pneumonia mortality, promote 
appropriate care seeking, and improve quality of care of 
health services. Tracking progress will be important to 
highlight problem areas and gaps and could inform 
priorities and planning. Improved data on childhood 
pneumonia episodes, hospital admissions, and deaths in 
each country obtained from District Health Information 
Systems, civil registration and vital statistics, and high-
quality epidemiological studies are required to accurately 
track trends, including identification and tracking of 
inequities at the subnational level. The widespread 
measurement of selected valid indicators of levels of 
appropriate care seeking and quality of care from health 
providers for child pneumonia would help guide priorities 
and investment to identify problems and achieve targets.
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